Division of Innovative Pathology and Laboratory Medicine (Tsukiji Campus)

Nobuyoshi Hiraoka, Satoshi Nakajima, Sachiyo Hasegawa

Introduction

In the Division of Innovative Pathology and Laboratory Medicine at the National Cancer Center (NCC) Tsukiji campus, we perform translational researches regarding tumor pathology and laboratory medicine aiming for the development and improvement of medical drugs and equipment. We act in cooperation with other related divisions such as the Department of Pathology and Clinical Laboratories in the NCC-Hospital (NCCH), and the Division of Molecular Pathology and the Department of Analytical Pathology in the NCC-Research Institute (NCCRI).

Research activities

We started to engage in the development of new laboratory tests that are related to tumor markers, monitoring host immunity and new technologies such as very high-resolution images.

Education

Teaching technicians and researchers the analytical techniques in several departments of the NCC was performed.

Future prospects

We will engage in the development of new tests in the field of pathology and laboratory medicine, and also provide information and new techniques for supporting the acceleration of medical innovation act in other groups.

List of papers published in 2016

Journal

1.Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, Gotoh K, Ariizumi S, Wardell CP, Hayami S, Nakamura T, Aikata H, Arihiro K, Boroevich KA, Abe T, Nakano K, Maejima K, Sasaki-Oku A, Ohsawa A, Shibuya T, Nakamura H, Hama N, Hosoda F, Arai Y, Ohashi S, Urushidate T, Nagae G, Yamamoto S, Ueda H, Tatsuno K, Ojima H, Hiraoka N, Okusaka T, Kubo M, Marubashi S, Yamada T, Hirano S, Yamamoto M, Ohdan H, Shimada K, Ishikawa O, Yamaue H, Chayama K, Miyano S, Aburatani H, Shibata T, Nakagawa H. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet, 48:500-509, 2016

2.Yachida S, Wood LD, Suzuki M, Takai E, Totoki Y, Kato M, Luchini C, Arai Y, Nakamura H, Hama N, Elzawahry A, Hosoda F, Shirota T, Morimoto N, Hori K, Funazaki J, Tanaka H, Morizane C, Okusaka T, Nara S, Shimada K, Hiraoka N, Taniguchi H, Higuchi R, Oshima M, Okano K, Hirono S, Mizuma M, Arihiro K, Yamamoto M, Unno M, Yamaue H, Weiss MJ, Wolfgang CL, Furukawa T, Nakagama H, Vogelstein B, Kiyono T, Hruban RH, Shibata T. Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. Cancer Cell, 29:229-240, 2016

3.Hiraoka N, Ino Y, Yamazaki-Itoh R. Tertiary Lymphoid Organs in Cancer Tissues. Front Immunol, 7:244, 2016

4.Mitsuma K, Taniguchi H, Kishi Y, Hiraoka N. A case of adenocarcinoma with enteroblastic differentiation of the ampulla of Vater. Pathol Int, 66:230-235, 2016

5.Morofuji N, Ojima H, Hiraoka N, Okusaka T, Esaki M, Nara S, Shimada K, Kishi Y, Kondo T. Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma. Clin Proteomics, 13:28, 2016

6.Hori S, Shimada K, Ino Y, Oguro S, Esaki M, Nara S, Kishi Y, Kosuge T, Hattori Y, Sukeda A, Kitagawa Y, Kanai Y, Hiraoka N. Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma. Virchows Arch, 469:621-634, 2016

7.Hori M, Onaya H, Hiraoka N, Yamaji T, Kobayashi H, Takahashi M, Mutoh M, Shimada K, Nakagama H. Evaluation of the degree of pancreatic fatty infiltration by area-based assessment of CT images: comparison with histopathology-based and CT attenuation index-based assessments. Jpn J Radiol, 34:667-676, 2016

8.Yoshida H, Shimada K, Kosuge T, Hiraoka N. A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. Virchows Arch, 468:431-439, 2016

9.Monma SE, Shimada K, Kishi Y, Nara S, Esaki M, Fujiki M, Miyamoto S, Hiraoka N. An extremely rare clinical manifestation of gallbladder cancer presenting with abdominal wall invasion with an erythematous skin break. Pathol Int, 66:302-304, 2016

10.Tada K, Maeshima AM, Hiraoka N, Yamauchi N, Maruyama D, Kim S-W, Watanabe T, Katayama N, Heike Y, Tobinai K, Kobayashi Y. Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy. Cancer Immunol Immunother, 65:1213-1222, 2016

11.Sekine S, Yamashita S, Tanabe T, Hashimoto T, Yoshida H, Taniguchi H, Kojima M, Shinmura K, Saito Y, Hiraoka N, Ushijima T, Ochiai A. Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma. J Pathol, 239:133-138, 2016

12.Shiba S, Morizane C, Hiraoka N, Sasaki M, Koga F, Sakamoto Y, Kondo S, Ueno H, Ikeda M, Yamada T, Shimada K, Kosuge T, Okusaka T. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. Pancreatology, 16:99-105, 2016

13.Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients. Cancer Immunol Res, 4:592-599, 2016